ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
Medicamen Biotech Limited held its 33rd Annual General Meeting on September 26, 2026. The meeting concluded after discussing standard business and special resolutions.
Medicamen Biotech Limited filed its notice for the 33rd Annual General Meeting scheduled for September 26, 2026, alongside the Integrated Annual Report for FY 2025-26.
Medicamen Biotech Limited has fixed September 19, 2026, as the record date for its final dividend. The book closure is scheduled from September 20 to September 26, 2026.
Medicamen Biotech Ltd reported revenue from operations of ₹4,790 Cr (+11.3% YoY) and net profit of ₹184.6 Cr (+15.3% YoY) for Q1 FY27.
Medicamen Biotech Ltd reported revenue from operations of ₹47.9 Cr (+11.4% YoY) and net profit of ₹1.8 Cr (+12.5% YoY) for Q1 FY27.
Medicamen Biotech Limited has scheduled a board meeting for August 14, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Medicamen Biotech Limited reported zero deviation in the utilization of ₹53.57 Crore raised via preferential issue. The funds are being deployed for drug development and expansion.
Medicamen Biotech Limited appointed M/s. Cheena & Associates and M/s. SPB & Co as Internal and Cost Auditors for 12 months. Both firms bring extensive professional experience to the company's audit functions.
Medicamen Biotech Limited's board approved the appointment of Cheena & Associates as internal auditors and SPB & Co as cost auditors. Both appointments are effective April 2026.
Medicamen Biotech recommended a final dividend of ₹10 per equity share for FY 2025-26. Book closure dates will be announced following the AGM schedule.
Medicamen Biotech Ltd reported revenue from operations of ₹60.6 Cr (+104.7% YoY) and net profit of ₹4.4 Cr (+131.6% YoY) for Q4 FY26.
Medicamen Biotech approved audited FY26 financial results and recommended a Rs. 1.00 per share final dividend. The board also appointed new cost and internal auditors.
Medicamen Biotech scheduled a board meeting for May 27, 2026. Directors will consider FY26 audited financial results and recommend a final dividend for the year.